Don't Take Your Vitamins
Paul Offit (New York TImes)
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
Luke Timmerman (Xconomy)
Be sure to head over to our SRPT home page for extensive coverage of Sarepta and their DMD drug eteplirsen from investing, scientific, and patient perspectives.
Legislation would Create New Incentives, Penalties to Compel Reporting of Trials Results
Alec Gaffney (Regulatory Focus)
I can count on one hand the number of listings I have seen on Clinicaltrials.gov that had the "required" results published - hopefully the situation will be improved somehow.
Master protocol’ aims to revamp cancer trials
Heidi Ledford (Nature)
FDA Issues Final Orphan Drug Regulations
Michelle Butler (FDA Law Blog)
Opinion recap: No patent on natural gene work
Lyle Denniston (SCOTUS Blog)
Solid summary of the Myriad Genetics MYGN patent case ruling re BRCA1/BRCA2.
Paul Offit (New York TImes)
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian
Luke Timmerman (Xconomy)
Be sure to head over to our SRPT home page for extensive coverage of Sarepta and their DMD drug eteplirsen from investing, scientific, and patient perspectives.
Legislation would Create New Incentives, Penalties to Compel Reporting of Trials Results
Alec Gaffney (Regulatory Focus)
I can count on one hand the number of listings I have seen on Clinicaltrials.gov that had the "required" results published - hopefully the situation will be improved somehow.
Master protocol’ aims to revamp cancer trials
Heidi Ledford (Nature)
FDA Issues Final Orphan Drug Regulations
Michelle Butler (FDA Law Blog)
Opinion recap: No patent on natural gene work
Lyle Denniston (SCOTUS Blog)
Solid summary of the Myriad Genetics MYGN patent case ruling re BRCA1/BRCA2.
RSS Feed
